OnKure Therapeutics (NASDAQ:OKUR) Upgraded to “Hold” at Wall Street Zen

OnKure Therapeutics (NASDAQ:OKUR) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other research firms have also recently issued reports on OKUR. Weiss Ratings raised shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. JonesTrading cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, HC Wainwright dropped their target price on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.00.

OnKure Therapeutics Price Performance

OKUR opened at $4.19 on Friday. The stock has a market capitalization of $169.28 million, a PE ratio of -0.97 and a beta of 0.28. The firm’s fifty day moving average price is $4.25 and its 200 day moving average price is $3.42. OnKure Therapeutics has a 12-month low of $1.91 and a 12-month high of $5.38.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.37). On average, equities research analysts forecast that OnKure Therapeutics will post -3.43 earnings per share for the current fiscal year.

Institutional Trading of OnKure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of OnKure Therapeutics during the second quarter worth $25,000. Jane Street Group LLC acquired a new stake in shares of OnKure Therapeutics during the fourth quarter worth $56,000. Hsbc Holdings PLC acquired a new stake in shares of OnKure Therapeutics during the fourth quarter worth $58,000. Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics during the second quarter worth $71,000. Finally, Barclays PLC raised its holdings in shares of OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after purchasing an additional 26,621 shares during the period. 90.98% of the stock is owned by institutional investors and hedge funds.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.